Ipratropium bromide and albuterol are bronchodilators used in combination to treat bronchospasm associated with chronic obstructive pulmonary disease (COPD) and other respiratory conditions [1].
How does the combination inhaler work?
The combination inhaler delivers ipratropium bromide, an anticholinergic, and albuterol sulfate, a short-acting beta2-adrenergic agonist [2]. Ipratropium bromide works by blocking the action of acetylcholine, a neurotransmitter that causes smooth muscles in the airways to contract [3]. Albuterol sulfate relaxes these same muscles by stimulating beta2-adrenergic receptors [4]. Together, these mechanisms open up the airways, making it easier to breathe [1].
What are the common brand names for ipratropium bromide/albuterol?
This combination medication is most commonly known by the brand name Combivent Respimat, which is a metered-dose inhaler [1]. It is also available as a nebulized solution under various brand names, including DuoNeb [5]. Generic versions are also available [1].
When does patent exclusivity expire for these medications?
Drug patent exclusivity for medications is a complex area that can be influenced by various factors, including new formulations and patent challenges. Information on the specific patent expiry dates for ipratropium bromide/albuterol formulations, including Combivent Respimat and DuoNeb, can be found by searching specialized databases. DrugPatentWatch.com offers detailed information on drug patents and exclusivity periods [6].
What are the potential side effects?
Common side effects reported with ipratropium bromide and albuterol combination inhalers include headache, cough, and throat irritation [1]. Other potential side effects can include dry mouth, nausea, urinary retention, and blurred vision, which are more commonly associated with the anticholinergic effects of ipratropium bromide [3]. Albuterol can also cause tremors and increased heart rate [4].
How does this combination compare to using albuterol alone?
Using ipratropium bromide and albuterol in combination can provide greater bronchodilation than albuterol alone for some patients, particularly those with COPD [1][4]. The dual mechanism of action addresses airway constriction through different pathways, potentially offering a more comprehensive relief for moderate to severe symptoms [2][3].
Can patients use ipratropium bromide and albuterol at different times?
While the combination inhaler is designed for concurrent administration, healthcare providers may sometimes recommend separate inhalers for ipratropium bromide and albuterol, allowing for individualized dosing and timing based on a patient's specific needs and symptom patterns [1][2].
What is the regulatory status of these medications?
Ipratropium bromide and albuterol combination products are approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of bronchospasm in patients with COPD [1].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/